clinical ai
The T4 Framework: How Precision Phenotyping Is Reshaping Severe Asthma Management
2026-06-12 · 3 min read
The Evolution Beyond Step-Up Therapy
For decades, severe asthma management followed a predictable pattern: step up therapy until symptoms improved, often cycling through the same biologics without clear phenotypic rationale. The Treat-to-Target by Treatable Traits (T4) framework represents a fundamental shift toward precision medicine, identifying specific inflammatory pathways and monitoring treatment responses across the entire patient journey.
The T4 approach recognizes that "severe asthma" encompasses multiple distinct endotypes—each requiring targeted intervention. Rather than sequential trial-and-error, clinicians can now identify treatable traits like eosinophilic inflammation, allergic sensitization patterns, or airway remodeling, then select therapies that address the underlying pathophysiology.
Identifying Treatable Traits in Practice
The framework emphasizes measurable, modifiable characteristics that predict treatment response. Key treatable traits include:
Type 2 Inflammation Markers: Elevated FeNO, blood eosinophilia (>300 cells/μL), or sputum eosinophilia (>3%) suggest IL-4, IL-5, or IL-13 pathway involvement—directly informing biologic selection.
Allergic Sensitization Patterns: Comprehensive allergen profiling reveals not just individual triggers, but cross-reactive patterns that influence environmental control strategies and immunotherapy candidacy.
Airway Dysfunction Metrics: Bronchodilator response, methacholine reactivity, and oscillometry findings help distinguish inflammatory from structural components.
Comorbid Conditions: GERD, chronic rhinosinusitis, and aspirin sensitivity often drive persistent symptoms despite optimal asthma therapy.
The Challenge of Longitudinal Tracking
T4's strength lies in monitoring these traits over time—but traditional documentation systems create significant barriers. Clinicians often struggle to track FeNO trends across visits, correlate symptom patterns with environmental exposures, or maintain comprehensive allergen sensitivity profiles as patients move through different phases of care.
Consider a typical severe asthma patient: initial evaluation reveals elevated FeNO (68 ppb), moderate eosinophilia, and sensitization to dust mites, tree pollens, and Aspergillus. After three months on dupilumab, FeNO drops to 22 ppb, but seasonal symptoms persist. Six months later, the patient reports new food reactions.
Without systematic trait tracking, these evolving patterns get lost in fragmented documentation. Providers may miss the connection between Aspergillus sensitivity and persistent symptoms, or fail to recognize emerging oral allergy syndrome in the context of existing tree pollen sensitivity.
Evidence-Based Phenotyping
Recent research emphasizes the importance of comprehensive phenotyping beyond traditional biomarkers. Emerging studies suggest that patients with multiple overlapping traits—such as aspirin sensitivity combined with chronic rhinosinusitis and nasal polyposis—may require coordinated interventions across specialties.
The key insight from T4 implementation studies is that successful precision management depends on consistent data capture and trend analysis. Clinicians need systems that automatically surface relevant historical data, highlight changing biomarker patterns, and maintain comprehensive allergen profiles across multiple encounters.
Real-World Implementation Challenges
Many clinics struggle with T4 implementation due to documentation burden. Tracking FeNO trends, maintaining detailed allergen sensitivity profiles, and correlating symptoms with environmental exposures requires significant clinical time—often leading to incomplete phenotyping.
The most successful implementations combine standardized assessment protocols with technology that reduces documentation overhead. When trait identification and monitoring become part of the natural workflow rather than additional tasks, clinicians can focus on clinical decision-making rather than data entry.
Supporting T4 Workflows with Integrated Documentation
Modern allergy practices are beginning to leverage AI-assisted documentation that maintains comprehensive patient phenotypes across visits. Systems like Medora AllergenIQ automatically track allergen sensitivity patterns and cross-reactivity relationships, while integrated modules ensure that skin test results, clinical notes, and follow-up assessments share unified patient context. Rather than recreating phenotypic profiles at each visit, providers can focus on interpreting evolving patterns and adjusting treatment strategies.
This longitudinal approach proves particularly valuable for complex patients with multiple treatable traits, where scattered documentation often obscures important clinical patterns that inform precision therapy decisions.